​

Charles River Laboratories (CRL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRL Stock Forecast

Charles River Laboratories (CRL) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $202.17, with a high of $260.00 and a low of $175.00. This represents a 32.09% increase from the last price of $153.05.

$150 $180 $210 $240 $270 $300 High: $260 Avg: $202.17 Low: $175 Last Closed Price: $153.05

CRL Stock Rating

Charles River Laboratories stock's rating consensus is Buy, based on 36 Wall Street analysts. The breakdown includes 1 Strong Buy (2.78%), 24 Buy (66.67%), 11 Hold (30.56%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 36 11 24 1 Strong Sell Sell Hold Buy Strong Buy

CRL Price Target Upside V Benchmarks

TypeNameUpside
StockCharles River Laboratories32.09%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks32.46%

Price Target Trends

1M3M12M
# Anlaysts-715
Avg Price Target-$214.00$204.13
Last Closing Price$153.05$153.05$153.05
Upside/Downside-39.82%33.37%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 261107--18
Feb, 261107--18
Jan, 261107--18
Dec, 25198--18
Nov, 25278-118
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 20, 2026Mizuho Securities$175.00$164.246.55%14.34%
Feb 19, 2026Eric ColdwellRobert W. Baird$193.00$158.1822.01%26.10%
Feb 19, 2026Luke SergottBarclays$200.00$158.0026.58%30.68%
Jan 13, 2026Robert W. Baird$231.00$221.694.20%50.93%
Jan 13, 2026Evercore ISI$260.00$225.1115.50%69.88%
Jan 09, 2026Eric ColdwellRobert W. Baird$224.00$219.492.05%46.36%
Jan 09, 2026Ann HynesMizuho Securities$215.00$215.51-0.24%40.48%
Dec 18, 2025Mizuho Securities$200.00$195.982.05%30.68%
Dec 15, 2025Barclays$215.00$192.9711.42%40.48%
Dec 01, 2025Kallum TitchmarshMorgan Stanley$185.00$176.095.06%20.88%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 20, 2026Cowen & Co.BuyBuyhold
Feb 19, 2026BarclaysOverweightOverweighthold
Jan 22, 2026Cowen & Co.BuyBuyhold
Jan 16, 2026CitigroupBuyBuyhold
Jan 13, 2026Evercore ISIOutperformOutperformhold
Dec 15, 2025Bank of America SecuritiesReduceBuyupgrade
Dec 15, 2025BarclaysOverweightOverweighthold
Oct 06, 2025William BlairOutperformupgrade
Oct 03, 2025Evercore ISIOutperformOutperformhold
Oct 02, 2025BarclaysEqual-WeightOverweightupgrade

Financial Forecast

EPS Forecast

$-5 $0 $5 $10 $15 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.77$9.57$9.27$0.20$-2.91---
Avg Forecast$10.26$10.89$10.59$10.19$9.88$11.00$12.43$14.23
High Forecast$10.51$11.15$10.68$10.30$12.56$12.63$15.07$15.26
Low Forecast$9.96$10.70$10.45$10.12$9.10$9.71$10.39$13.52
Surprise %-24.27%-12.12%-12.46%-98.04%-129.45%---

Revenue Forecast

$3B $3B $4B $4B $5B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.54B$3.98B$4.13B$4.05B$4.02B---
Avg Forecast$3.52B$3.91B$4.11B$4.03B$3.93B$4.16B$4.37B$4.63B
High Forecast$3.59B$3.98B$4.12B$4.05B$4.07B$4.18B$4.42B$4.89B
Low Forecast$3.44B$3.86B$4.10B$4.02B$3.77B$4.15B$4.31B$4.46B
Surprise %0.50%1.64%0.55%0.47%2.23%---

Net Income Forecast

$-150M $40M $230M $420M $610M $800M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$390.98M$486.23M$474.62M$10.30M$-144.34M---
Avg Forecast$364.08M$454.69M$474.62M$525.43M$557.17M$574.85M$654.91M$732.15M
High Forecast$436.89M$545.62M$569.55M$530.07M$646.04M$650.02M$775.34M$785.01M
Low Forecast$291.26M$363.75M$379.70M$520.79M$468.30M$499.69M$534.47M$695.76M
Surprise %7.39%6.94%--98.04%-125.91%---

CRL Forecast FAQ

Is Charles River Laboratories stock a buy?

Charles River Laboratories stock has a consensus rating of Buy, based on 36 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 24 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Charles River Laboratories is a favorable investment for most analysts.

What is Charles River Laboratories's price target?

Charles River Laboratories's price target, set by 36 Wall Street analysts, averages $202.17 over the next 12 months. The price target range spans from $175 at the low end to $260 at the high end, suggesting a potential 32.09% change from the previous closing price of $153.05.

How does Charles River Laboratories stock forecast compare to its benchmarks?

Charles River Laboratories's stock forecast shows a 32.09% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (32.46%).

What is the breakdown of analyst ratings for Charles River Laboratories over the past three months?

  • March 2026: 5.56% Strong Buy, 55.56% Buy, 38.89% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 5.56% Strong Buy, 55.56% Buy, 38.89% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 5.56% Strong Buy, 55.56% Buy, 38.89% Hold, 0% Sell, 0% Strong Sell.

What is Charles River Laboratories’s EPS forecast?

Charles River Laboratories's average annual EPS forecast for its fiscal year ending in December 2026 is $11, marking a -478.01% decrease from the reported $-2.91 in 2025. Estimates for the following years are $12.43 in 2027, and $14.23 in 2028.

What is Charles River Laboratories’s revenue forecast?

Charles River Laboratories's average annual revenue forecast for its fiscal year ending in December 2026 is $4.16B, reflecting a 3.68% increase from the reported $4.02B in 2025. The forecast for 2027 is $4.37B, and $4.63B for 2028.

What is Charles River Laboratories’s net income forecast?

Charles River Laboratories's net income forecast for the fiscal year ending in December 2026 stands at $574.85M, representing a -498.27% decrease from the reported $-144M in 2025. Projections indicate $654.91M in 2027, and $732.15M in 2028.